piracetam has been researched along with ketamine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Zhang, LH; Zhang, SS | 1 |
| Sprints, AM | 1 |
| di Martino, MR; Marchi, A; Passino, N; Saba, G | 1 |
| Gulati, S; Lodha, R; Raj, D | 1 |
| Brigo, F; Höfler, J; Kalss, G; Leitinger, M; Rohracher, A; Trinka, E | 1 |
| Ambrosi, M; Pavone, P; Striano, P; Verrotti, A | 1 |
| Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y | 1 |
| Anastasio, NC; Cunningham, KA; Davis-Reyes, BD; Smith, AE; Xu, J; Zhou, J | 1 |
| Andrade, C | 1 |
3 review(s) available for piracetam and ketamine
| Article | Year |
|---|---|
Pharmacologic treatment of status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Humans; Ketamine; Levetiracetam; Piracetam; Randomized Controlled Trials as Topic; Seizures; Status Epilepticus; Treatment Failure; Valproic Acid | 2016 |
Pediatric status epilepticus: improved management with new drug therapies?
Topics: Algorithms; Anticonvulsants; Child; Clinical Protocols; Humans; Ketamine; Levetiracetam; Midazolam; Piracetam; Prospective Studies; Retrospective Studies; Status Epilepticus; Valproic Acid | 2017 |
Reconsideration of the Benefits of Pharmacological Interventions for the Attenuation of the Cognitive Adverse Effects of Electroconvulsive Therapy.
Topics: Calcium Channel Blockers; Cholinesterase Inhibitors; Cognition; Electroconvulsive Therapy; Humans; Hydrocortisone; Ketamine; Melatonin; Memantine; Narcotic Antagonists; Nortriptyline; Pemoline; Piracetam; Treatment Outcome; Triiodothyronine; Tryptophan | 2022 |
7 other study(ies) available for piracetam and ketamine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Relationship between facilitatory effect of piracetam on memory and glutamate receptors].
Topics: Animals; Brain; Discrimination Learning; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Ketamine; Male; Memory; Mice; Piracetam; Receptors, Glutamate; Receptors, Neurotransmitter | 1991 |
[The mechanisms of memory disorders at the stages in its acquisition and fixation].
Topics: Amnesia; Animals; Avoidance Learning; Conditioning, Classical; Dose-Response Relationship, Drug; Female; Ketamine; Memory Disorders; Memory, Short-Term; Piracetam; Rats; Receptors, Muscarinic; Scopolamine; Time Factors | 1988 |
[Piracetam treatment of pseudohallucinatory phenomena induced by ketamine].
Topics: Adolescent; Adult; Anesthesia, General; Female; Hallucinations; Humans; Ketamine; Male; Piracetam; Pyrrolidinones | 1983 |
Status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Clinical Protocols; Fructose; GABA Modulators; Humans; Ketamine; Levetiracetam; Midazolam; Pentobarbital; Phenobarbital; Phenytoin; Piracetam; Propofol; Status Epilepticus; Thiopental; Topiramate; Valproic Acid | 2011 |
Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Ketamine; Levetiracetam; Locomotion; Male; Maze Learning; Memory Disorders; Nootropic Agents; Piracetam; Rats; Rats, Long-Evans; Schizophrenia | 2018 |
Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats.
Topics: Animals; Antidepressive Agents; Cognition; Dose-Response Relationship, Drug; Glutamic Acid; Impulsive Behavior; Ketamine; Mental Disorders; Neuronal Plasticity; Nootropic Agents; Piracetam; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 2021 |